Sweet as sugar
| |
 |
| |
The company
has opened up new horizons in direct compression. |
In the manufacture of lactose-based excipients,
a number of factors need to be considered:
granulation, capsule filling, direct compression
and dry-powder delivery. MEGGLE’s range of
innovative products delivers on all these points
and more.
MEGGLE enjoys an enviable reputation throughout
the world as a leading pharmaceutical lactose
supplier. With its high-quality products and
intelligent innovations, the organisation has
achieved a prime
position in the manufacture of excipients. It
has been active
in the market for more than 50 years and in that
time has
developed a broad product portfolio second to
none.
In addition to excipients for granulation and
capsule filling, it
includes special cutting-edge products for direct
compression
and dry-powder inhalers. With the launch and further
development of its compounds, the company has
opened up
new horizons in direct compression and set new
international
standards. Its clients are mainly producers of
pharmaceutical
products and nutritional supplements. However,
the
functionality of its products is also appreciated
by other
sectors, including the cosmetics and detergent
industries.
Innovation and service
The company knows that you, the user, demand absolutely
inert excipients that have no activity of their
own and do not
interact with the active substances in any other
ingredients.
You also expect them to meet your requirements
in the various
areas of application. These are complex demands
that call not
only for innovative products but also for intensive
consultation.
Customers therefore have access to an experienced
team of
experts to assist them in the development, production,
application and refinement of excipients.
Whether the company is involved in custom manufacturing
or a development cooperation agreement, its objective
is always to
share its knowledge with its partners. As a manufacturer
committed
to innovation, it is in constant contact with
numerous scientific
institutions throughout the world. This ensures
that the latest
research findings are fed back into its work day
after day. As
a MEGGLE customer, you can rest assured that you
will always be
provided with state-of-the-art products and services.
To ensure
that quality remains high for long periods, the
company pays
particular attention to storage stability. Its
FlowLac 100, for
example, has the longest storage stability of
any spray-dried
lactose; it beats all competing products by more
than 50%.
Quality is king
All MEGGLE pharmaceutical lactose types comply
with the
monograph ‘lactose monohydrate’ of the
European
Pharmacopoeia (Ph Eur). This monograph has been
harmonised
between Ph Eur, USP/NF and JP. The company’s
sieved, milled,
agglomerated or spray-dried lactoses and its co-processed
excipients exceed all international quality standards.
As a result, excipients from MEGGLE offer constant,
reliable, cutting-edge quality. High investment
in R&D keep
the organisation one step ahead of the competition.
All the
products have to pass a series of strict quality
tests before
they are put on the market, and the production
process itself
is subject to constant multi-stage quality controls.
Products for direct compression are a particular
highlight of
the organisation’s excipient portfolio. By
‘co-processing’ two
different excipients, it is possible to achieve
a synergy of ideal
characteristics that greatly simplifies and accelerates
tablet
production. MEGGLE was one of the first manufacturers
to
produce a co-processed compound.
The company’s mission
As a leading lactose manufacturer, MEGGLE is committed
to offering its customers throughout the world
the best
products for their particular applications. Its
products already
exceed international quality standards, and it
is constantly
expanding its scope of services to maximise customer
focus.
MEGGLE’s vision
These are the company’s long-term objectives:
- Maximising benefits for customers by developing
innovative high-tech products, including products
for new
forms of application
- Expanding its leading position as an independent
producer
in the development and improvement of excipients
- Supporting customers in the development of
new
formulations
- Expanding its global network of offices and
subsidiaries
|
